Skip to content

Innate Immune Response in COPD

Innate Immune Response in COPD

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02637219
Enrollment
30
Registered
2015-12-22
Start date
2006-03-31
Completion date
2008-01-31
Last updated
2015-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchitis, Chronic, Immunity, Innate, Inflammation, Pulmonary Disease, Chronic Obstructive, Toll-Like Receptors

Brief summary

The purpose of this study is to determine whether the response of the immune system to bacterial components differs between patients with severe COPD compared to those with less severe COPD.

Detailed description

The airways of COPD patients are often colonized with bacteria leading to increased airway inflammation. This study sought to determine whether systemic cytokine responses to microbial pathogen-associated molecular patterns (PAMPs) are increased among subjects with severe COPD. In an observational cross-sectional study of COPD subjects, PAMP-induced cytokine responses were measured in whole blood ex vivo. We used PAMPs derived from microbial products recognized by TLR 1, 2, 4, 5, 6, 7, and 8. Patterns of cytokine response to PAMPs were assessed using hierarchical clustering. One-sided t-tests were used to compare PAMP-induced cytokine levels in blood from patients with and without severe COPD, and for subjects with and without chronic bronchitis.

Interventions

None listed

Sponsors

University of Washington
CollaboratorOTHER
Novartis Pharmaceuticals
CollaboratorINDUSTRY
VA Puget Sound Health Care System
Lead SponsorFED

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
MALE
Age
50 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* post-bronchodilator FEV1/FVC \<0.7 * FEV1 \< 80% * \> 10 pack-years tobacco smoking * no respiratory illnesses or prednisone or antibiotics in the last 4 weeks

Exclusion criteria

* Primary diagnosis of asthma * \> 15% change in FEV1 * Chronic inflammatory or infectious disease * Cancer * Autoimmune disease * Chronic renal failure with a creatinine \> 1.5 * Chronic liver disease * Chronic antibiotic use Note: Due to difficulty recruiting patients after 6 participants were enrolled, the

Design outcomes

Primary

MeasureTime frameDescription
Cytokine production (TNF-alpha, IL-6, IL-8, IL-10, IL-1RA, G-CSF, IL-1B, MCP-1).This is a cross-sectional study with no follow-up period. Therefore the study outcomes were measured at the baseline visit (Time = day 0)A whole blood stimulation assay was performed on blood samples from study participants. The whole blood was stimulated using several pathogen-associated molecular patterns that were agonists to seven different TLR receptors: 1) Pam3SCK4, 2) Zymosan, 3) FSL-1, 4) LPS, 5) flagellin, 6) R848. After stimulation with the PAMP, the cytokine levels (TNF-alpha, IL-6, IL-8, IL-10, IL-1RA, G-CSF, IL-1B, and MCP-1) were measured and the cytokine level results are in picograms per liter. Note, there is no treatment in this observational non-interventional trial. Therefore the multiple cytokine levels for each patient will not be aggregated or summarized into one measure. This study was a small pilot study and the results are exploratory.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026